+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Efficiency of 1-Year Treatment with Fluvastatin in Hyperlipidemic Patients with Nephrotic Syndrome

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The influence of fluvastatin, a liver-selective, competitive inhibitor of the 3-hydroxymethyl-glutaryl-coenzyme A reductase, on the lipoprotein metabolism was investigated in 9 patients with nephrotic syndrome. All patients had biopsy-proven renal disease as cause of their nephrotic syndrome and exhibited severe hyperlipidemia [baseline: serum cholesterol 358 ± 46 mg/dl (9.3 mmol/l), low-density lipoprotein cholesterol 236 ± 18 mg/dl (6.1 mmol/l), triglyerides 333 ± 28 mg/dl (3.8 mmol/l), and lipoprotein Lp(a) 46 ± 11 mg/dl]. After 1 year of 40 mg of fluvastatin, significant reductions of total cholesterol by 31% to 242 ± 26 mg/dl (6.3 mmol/l) and low-density lipoprotein cholesterol by 29% to 162 ± 12 mg/dl (4.2 mmol/l) were observed. Furthermore, triglyceride values were also lowered significantly by 19% to 268 ± 21 mg/dl (3.1 mmol/l). Lipoprotein Lp(a) and high-density lipoprotein-cholesterol remained unchanged by fluvastatin. These improvements in lipid profile were maintained during the entire follow-up period of 1 year. There were no adverse events, and the slight increase in serum creatinine observed during the study was considered to be due to the primary renal disease. In conclusion, long- term administration of fluvastatin in patients with nephrotic syndrome appears to be an effective and safe treatment of the hyperlipidemia associated with this disorder.

          Related collections

          Author and article information

          Am J Nephrol
          American Journal of Nephrology
          S. Karger AG
          August 1999
          13 August 1999
          : 19
          : 4
          : 492-494
          aDepartment of Internal Medicine, University of Münster, and bKfH Dialysis Center and Outpatient Clinic, Würzburg, Germany
          13504 Am J Nephrol 1999;19:492–494
          © 1999 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Tables: 2, References: 11, Pages: 3
          Self URI (application/pdf):
          Clinical Study


          Comment on this article